Yi Jia1, Huifeng Yu2, Steve M Fernandes2, Yadong Wei2, Anabel Gonzalez-Gil2, Mary G Motari2, Katarina Vajn2, Whitney W Stevens3, Anju T Peters3, Bruce S Bochner3, Robert C Kern4, Robert P Schleimer3, Ronald L Schnaar5. 1. Department of Pharmacology, Third Military Medical University, Chongqing, China; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Md. 2. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Md. 3. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. 4. Department of Otorhinolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill. 5. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: schnaar@jhu.edu.
Abstract
BACKGROUND: Balanced activation and inhibition of the immune system ensures pathogen clearance while avoiding hyperinflammation. Siglecs, sialic acid-binding proteins found on subsets of immune cells, often inhibit inflammation: Siglec-8 on eosinophils and Siglec-9 on neutrophils engage sialoglycan ligands on airways to diminish ongoing inflammation. The identities of human siglec ligands and their expression during inflammation are largely unknown. OBJECTIVE: The histologic distribution, expression, and molecular characteristics of siglec ligands were explored in healthy and inflamed human upper airways and in a cellular model of airway inflammation. METHODS: Normal and chronically inflamed upper airway tissues were stained for siglec ligands. The ligands were extracted from normal and inflamed tissues and from human Calu-3 cells for quantitative analysis by means of siglec blotting and isolation by means of siglec capture. RESULTS: Siglec-8 ligands were expressed on a subpopulation of submucosal gland cells of human inferior turbinate, whereas Siglec-9 ligands were expressed more broadly (submucosal glands, epithelium, and connective tissue); both were significantly upregulated in patients with chronic rhinosinusitis. Human airway (Calu-3) cells expressed Siglec-9 ligands on mucin 5B (MUC5B) under inflammatory control through the nuclear factor κB pathway, and MUC5B carried sialoglycan ligands of Siglec-9 on human upper airway tissue. CONCLUSION: Inflammation results in upregulation of immune-inhibitory Siglec-8 and Siglec-9 sialoglycan ligands on human airways. Siglec-9 ligands are upregulated through the nuclear factor κB pathway, resulting in their enhanced expression on MUC5B. Siglec sialoglycan ligand expression in inflamed cells and tissues may contribute to the control of airway inflammation.
BACKGROUND: Balanced activation and inhibition of the immune system ensures pathogen clearance while avoiding hyperinflammation. Siglecs, sialic acid-binding proteins found on subsets of immune cells, often inhibit inflammation: Siglec-8 on eosinophils and Siglec-9 on neutrophils engage sialoglycan ligands on airways to diminish ongoing inflammation. The identities of human siglec ligands and their expression during inflammation are largely unknown. OBJECTIVE: The histologic distribution, expression, and molecular characteristics of siglec ligands were explored in healthy and inflamed human upper airways and in a cellular model of airway inflammation. METHODS: Normal and chronically inflamed upper airway tissues were stained for siglec ligands. The ligands were extracted from normal and inflamed tissues and from human Calu-3 cells for quantitative analysis by means of siglec blotting and isolation by means of siglec capture. RESULTS:Siglec-8 ligands were expressed on a subpopulation of submucosal gland cells of human inferior turbinate, whereas Siglec-9 ligands were expressed more broadly (submucosal glands, epithelium, and connective tissue); both were significantly upregulated in patients with chronic rhinosinusitis. Human airway (Calu-3) cells expressed Siglec-9 ligands on mucin 5B (MUC5B) under inflammatory control through the nuclear factor κB pathway, and MUC5B carried sialoglycan ligands of Siglec-9 on human upper airway tissue. CONCLUSION:Inflammation results in upregulation of immune-inhibitory Siglec-8 and Siglec-9 sialoglycan ligands on human airways. Siglec-9 ligands are upregulated through the nuclear factor κB pathway, resulting in their enhanced expression on MUC5B. Siglec sialoglycan ligand expression in inflamed cells and tissues may contribute to the control of airway inflammation.
Authors: Stephan von Gunten; Shida Yousefi; Michael Seitz; Stephan M Jakob; Thomas Schaffner; Reinhard Seger; Jukka Takala; Peter M Villiger; Hans-Uwe Simon Journal: Blood Date: 2005-04-12 Impact factor: 22.113
Authors: Bruce S Bochner; Richard A Alvarez; Padmaja Mehta; Nicolai V Bovin; Ola Blixt; John R White; Ronald L Schnaar Journal: J Biol Chem Date: 2004-11-24 Impact factor: 5.157
Authors: Susana M Casalino-Matsuda; Maria Elena Monzon; Gregory E Conner; Matthias Salathe; Rosanna M Forteza Journal: J Biol Chem Date: 2004-02-26 Impact factor: 5.157
Authors: Johannes M Pröpster; Fan Yang; Said Rabbani; Beat Ernst; Frédéric H-T Allain; Mario Schubert Journal: Proc Natl Acad Sci U S A Date: 2016-06-29 Impact factor: 11.205
Authors: Cheng Peng; Evelien R Van Meel; Andres Cardenas; Sheryl L Rifas-Shiman; Abhijeet R Sonawane; Kimberly R Glass; Diane R Gold; Thomas A Platts-Mills; Xihong Lin; Emily Oken; Marie-France Hivert; Andrea A Baccarelli; Nicolette W De Jong; Janine F Felix; Vincent W Jaddoe; Liesbeth Duijts; Augusto A Litonjua; Dawn L DeMeo Journal: Epigenetics Date: 2019-03-28 Impact factor: 4.528
Authors: Huifeng Yu; Anabel Gonzalez-Gil; Yadong Wei; Steve M Fernandes; Ryan N Porell; Katarina Vajn; James C Paulson; Corwin M Nycholat; Ronald L Schnaar Journal: Glycobiology Date: 2017-07-01 Impact factor: 4.313
Authors: Fanny Legrand; Nadine Landolina; Ilan Zaffran; Robert O Emeh; Elizabeth Chen; Amy D Klion; Francesca Levi-Schaffer Journal: Allergy Date: 2019-02-26 Impact factor: 13.146